Cargando…

Telemedicine-Based Specialized Care Improves the Outcome of Anticoagulated Individuals with Venous Thromboembolism—Results from the thrombEVAL Study

Venous thromboembolism (VTE) is a life-threatening disease with risk of recurrence. Oral anticoagulation (OAC) with vitamin K antagonists (VKA) is effective to prevent thromboembolic recurrence. We aimed to investigate the quality of OAC of VTE patients in regular medical care (RMC) compared to a te...

Descripción completa

Detalles Bibliográficos
Autores principales: Keller, Karsten, Göbel, Sebastian, ten Cate, Vincent, Panova-Noeva, Marina, Eggebrecht, Lisa, Nagler, Markus, Coldewey, Meike, Foebel, Maike, Bickel, Christoph, Lauterbach, Michael, Espinola-Klein, Christine, Lackner, Karl J., ten Cate, Hugo, Münzel, Thomas, S. Wild, Philipp, H. Prochaska, Jürgen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7602093/
https://www.ncbi.nlm.nih.gov/pubmed/33066188
http://dx.doi.org/10.3390/jcm9103281
_version_ 1783603590073417728
author Keller, Karsten
Göbel, Sebastian
ten Cate, Vincent
Panova-Noeva, Marina
Eggebrecht, Lisa
Nagler, Markus
Coldewey, Meike
Foebel, Maike
Bickel, Christoph
Lauterbach, Michael
Espinola-Klein, Christine
Lackner, Karl J.
ten Cate, Hugo
Münzel, Thomas
S. Wild, Philipp
H. Prochaska, Jürgen
author_facet Keller, Karsten
Göbel, Sebastian
ten Cate, Vincent
Panova-Noeva, Marina
Eggebrecht, Lisa
Nagler, Markus
Coldewey, Meike
Foebel, Maike
Bickel, Christoph
Lauterbach, Michael
Espinola-Klein, Christine
Lackner, Karl J.
ten Cate, Hugo
Münzel, Thomas
S. Wild, Philipp
H. Prochaska, Jürgen
author_sort Keller, Karsten
collection PubMed
description Venous thromboembolism (VTE) is a life-threatening disease with risk of recurrence. Oral anticoagulation (OAC) with vitamin K antagonists (VKA) is effective to prevent thromboembolic recurrence. We aimed to investigate the quality of OAC of VTE patients in regular medical care (RMC) compared to a telemedicine-based coagulation service (CS). The thrombEVAL study (NCT01809015) is a prospective, multi-center study to investigate OAC treatment (recruitment: January 2011–March 2013). Patients were evaluated using clinical visits, computer-assisted personal interviews, self-reported data and laboratory measurements according to standard operating procedures. Overall, 360 patients with VTE from RMC and 254 from CS were included. Time in therapeutic range (TTR) was higher in CS compared to RMC (76.9% (interquartile range [IQR] 63.2–87.1%) vs. 69.5% (52.3–85.6%), p < 0.001). Crude rate of thromboembolic events (rate ratio [RR] 11.33 (95% confidence interval [CI] 1.85–465.26), p = 0.0015), clinically relevant bleeding (RR 6.80 (2.52–25.76), p < 0.001), hospitalizations (RR 2.54 (1.94–3.39), p < 0.001) and mortality under OAC (RR 5.89 (2.40–18.75), p < 0.001) were consistently higher in RMC compared with CS. Patients in RMC had higher risk for primary outcome (clinically relevant bleedings, thromboembolic events and mortality, hazard ratio [HR] 5.39 (95%CI 2.81–10.33), p < 0.0001), mortality (HR 5.54 (2.22–13.84), p = 0.00025), thromboembolic events (HR 6.41 (1.51–27.24), p = 0.012), clinically relevant bleeding (HR 5.31 (1.89–14.89), p = 0.0015) and hospitalization (HR 1.84 (1.34–2.55), p = 0.0002). Benefits of CS care were still observed after adjusting for comorbidities and TTR. In conclusion, anticoagulation quality and outcome of VTE patients undergoing VKA treatment was significantly better in CS than in RMC. Patients treated in CS had lower rates of adverse events, hospitalizations and lower mortality. CS was prognostically relevant, beyond providing advantages of improved international ratio (INR) monitoring.
format Online
Article
Text
id pubmed-7602093
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-76020932020-11-01 Telemedicine-Based Specialized Care Improves the Outcome of Anticoagulated Individuals with Venous Thromboembolism—Results from the thrombEVAL Study Keller, Karsten Göbel, Sebastian ten Cate, Vincent Panova-Noeva, Marina Eggebrecht, Lisa Nagler, Markus Coldewey, Meike Foebel, Maike Bickel, Christoph Lauterbach, Michael Espinola-Klein, Christine Lackner, Karl J. ten Cate, Hugo Münzel, Thomas S. Wild, Philipp H. Prochaska, Jürgen J Clin Med Article Venous thromboembolism (VTE) is a life-threatening disease with risk of recurrence. Oral anticoagulation (OAC) with vitamin K antagonists (VKA) is effective to prevent thromboembolic recurrence. We aimed to investigate the quality of OAC of VTE patients in regular medical care (RMC) compared to a telemedicine-based coagulation service (CS). The thrombEVAL study (NCT01809015) is a prospective, multi-center study to investigate OAC treatment (recruitment: January 2011–March 2013). Patients were evaluated using clinical visits, computer-assisted personal interviews, self-reported data and laboratory measurements according to standard operating procedures. Overall, 360 patients with VTE from RMC and 254 from CS were included. Time in therapeutic range (TTR) was higher in CS compared to RMC (76.9% (interquartile range [IQR] 63.2–87.1%) vs. 69.5% (52.3–85.6%), p < 0.001). Crude rate of thromboembolic events (rate ratio [RR] 11.33 (95% confidence interval [CI] 1.85–465.26), p = 0.0015), clinically relevant bleeding (RR 6.80 (2.52–25.76), p < 0.001), hospitalizations (RR 2.54 (1.94–3.39), p < 0.001) and mortality under OAC (RR 5.89 (2.40–18.75), p < 0.001) were consistently higher in RMC compared with CS. Patients in RMC had higher risk for primary outcome (clinically relevant bleedings, thromboembolic events and mortality, hazard ratio [HR] 5.39 (95%CI 2.81–10.33), p < 0.0001), mortality (HR 5.54 (2.22–13.84), p = 0.00025), thromboembolic events (HR 6.41 (1.51–27.24), p = 0.012), clinically relevant bleeding (HR 5.31 (1.89–14.89), p = 0.0015) and hospitalization (HR 1.84 (1.34–2.55), p = 0.0002). Benefits of CS care were still observed after adjusting for comorbidities and TTR. In conclusion, anticoagulation quality and outcome of VTE patients undergoing VKA treatment was significantly better in CS than in RMC. Patients treated in CS had lower rates of adverse events, hospitalizations and lower mortality. CS was prognostically relevant, beyond providing advantages of improved international ratio (INR) monitoring. MDPI 2020-10-13 /pmc/articles/PMC7602093/ /pubmed/33066188 http://dx.doi.org/10.3390/jcm9103281 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Keller, Karsten
Göbel, Sebastian
ten Cate, Vincent
Panova-Noeva, Marina
Eggebrecht, Lisa
Nagler, Markus
Coldewey, Meike
Foebel, Maike
Bickel, Christoph
Lauterbach, Michael
Espinola-Klein, Christine
Lackner, Karl J.
ten Cate, Hugo
Münzel, Thomas
S. Wild, Philipp
H. Prochaska, Jürgen
Telemedicine-Based Specialized Care Improves the Outcome of Anticoagulated Individuals with Venous Thromboembolism—Results from the thrombEVAL Study
title Telemedicine-Based Specialized Care Improves the Outcome of Anticoagulated Individuals with Venous Thromboembolism—Results from the thrombEVAL Study
title_full Telemedicine-Based Specialized Care Improves the Outcome of Anticoagulated Individuals with Venous Thromboembolism—Results from the thrombEVAL Study
title_fullStr Telemedicine-Based Specialized Care Improves the Outcome of Anticoagulated Individuals with Venous Thromboembolism—Results from the thrombEVAL Study
title_full_unstemmed Telemedicine-Based Specialized Care Improves the Outcome of Anticoagulated Individuals with Venous Thromboembolism—Results from the thrombEVAL Study
title_short Telemedicine-Based Specialized Care Improves the Outcome of Anticoagulated Individuals with Venous Thromboembolism—Results from the thrombEVAL Study
title_sort telemedicine-based specialized care improves the outcome of anticoagulated individuals with venous thromboembolism—results from the thrombeval study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7602093/
https://www.ncbi.nlm.nih.gov/pubmed/33066188
http://dx.doi.org/10.3390/jcm9103281
work_keys_str_mv AT kellerkarsten telemedicinebasedspecializedcareimprovestheoutcomeofanticoagulatedindividualswithvenousthromboembolismresultsfromthethrombevalstudy
AT gobelsebastian telemedicinebasedspecializedcareimprovestheoutcomeofanticoagulatedindividualswithvenousthromboembolismresultsfromthethrombevalstudy
AT tencatevincent telemedicinebasedspecializedcareimprovestheoutcomeofanticoagulatedindividualswithvenousthromboembolismresultsfromthethrombevalstudy
AT panovanoevamarina telemedicinebasedspecializedcareimprovestheoutcomeofanticoagulatedindividualswithvenousthromboembolismresultsfromthethrombevalstudy
AT eggebrechtlisa telemedicinebasedspecializedcareimprovestheoutcomeofanticoagulatedindividualswithvenousthromboembolismresultsfromthethrombevalstudy
AT naglermarkus telemedicinebasedspecializedcareimprovestheoutcomeofanticoagulatedindividualswithvenousthromboembolismresultsfromthethrombevalstudy
AT coldeweymeike telemedicinebasedspecializedcareimprovestheoutcomeofanticoagulatedindividualswithvenousthromboembolismresultsfromthethrombevalstudy
AT foebelmaike telemedicinebasedspecializedcareimprovestheoutcomeofanticoagulatedindividualswithvenousthromboembolismresultsfromthethrombevalstudy
AT bickelchristoph telemedicinebasedspecializedcareimprovestheoutcomeofanticoagulatedindividualswithvenousthromboembolismresultsfromthethrombevalstudy
AT lauterbachmichael telemedicinebasedspecializedcareimprovestheoutcomeofanticoagulatedindividualswithvenousthromboembolismresultsfromthethrombevalstudy
AT espinolakleinchristine telemedicinebasedspecializedcareimprovestheoutcomeofanticoagulatedindividualswithvenousthromboembolismresultsfromthethrombevalstudy
AT lacknerkarlj telemedicinebasedspecializedcareimprovestheoutcomeofanticoagulatedindividualswithvenousthromboembolismresultsfromthethrombevalstudy
AT tencatehugo telemedicinebasedspecializedcareimprovestheoutcomeofanticoagulatedindividualswithvenousthromboembolismresultsfromthethrombevalstudy
AT munzelthomas telemedicinebasedspecializedcareimprovestheoutcomeofanticoagulatedindividualswithvenousthromboembolismresultsfromthethrombevalstudy
AT swildphilipp telemedicinebasedspecializedcareimprovestheoutcomeofanticoagulatedindividualswithvenousthromboembolismresultsfromthethrombevalstudy
AT hprochaskajurgen telemedicinebasedspecializedcareimprovestheoutcomeofanticoagulatedindividualswithvenousthromboembolismresultsfromthethrombevalstudy